Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 10, 2026BMC NeurologyOpen Access

Efficacy and safety of low-dose trazodone hydrochloride for insomnia in patients with myasthenia gravis

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJingting PengXKXiuyun KongRLR Q Li

Discussion

Loading...

Member takes

Overview

Retrospective study shows trazodone improves insomnia in myasthenia gravis patients, indicating its safety.

Key Points

  • This study aims to evaluate the efficacy and safety of low-dose trazodone hydrochloride for treating insomnia in patients with myasthenia gravis.
  • Retrospective analysis of clinical data from MG patients with insomnia receiving low-dose trazodone (25–100 mg nightly for ≥ 4 weeks).
  • Patients stratified into three groups based on Self-Rating Depression Scale (SDS) scores.
  • Changes in PSQI, SDS, and MG-ADL scores were analyzed before and after treatment.
  • Total of 68 MG patients enrolled with notable improvements in PSQI scores (all p < 0.01).
  • Significant decrease in SDS scores in the mild depression group (p < 0.01), but not in the moderate-to-severe group.
  • Mild adverse events occurred in 5.9% of patients, including hypotension, dizziness, and nausea.

Cite This Study

Peng et al. (2026) studied this question.

synapsesocial.com/papers/6a0020cec8f74e3340f9b969https://doi.org/10.1186/s12883-026-04962-x
View Full Paper
Ask AI
Bookmark
Share